TNFα-blocking agents, including infliximab (IFX), have revolutionized the treatment of moderate to severe inflammatory bowel disease and have been reported to induce rapid symptom resolution and to facilitate steroid tapering even in CS-refractory irEC cases [16]. Here, TNF is linked to inflammatory bowel disease.